Allopurinol kinetics and bioavailability
- 1 April 1982
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 8 (1) , 93-98
- https://doi.org/10.1007/bf00292878
Abstract
Six normal, healthy adult males received a single dose of allopurinol intravenously, orally in the form of a commercial tablet, and rectally in the form of an extemperaneously prepared suppository (either in a cocoa butter or in polyethylene glycol base). Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean (±SD) values were obtained from the intravenous allopurinol experiment: clearance, 9.62±3.49 ml · kg-1 · min-1; Vd, 1.61±0.74 l/kg; t1/2, 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23%, while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects. Current use of rectal dosage forms as an adjunct in cancer chemotherapy should therefore be re-examined.Keywords
This publication has 14 references indexed in Scilit:
- Bioavailability of allopurinol oral and rectal dosage formsAmerican Journal of Health-System Pharmacy, 1981
- Allopurinol kineticsClinical Pharmacology & Therapeutics, 1978
- Statistical estimations in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1974
- Renal clearance of oxipurinol, the chief metabolite of allopurinolThe American Journal of Medicine, 1968
- Metabolic studies of allopurinol, an inhibitor of xanthine oxidaseBiochemical Pharmacology, 1966
- Metabolic and therapeutic effects of allopurinol in patients with leukemia and goutThe American Journal of Medicine, 1966
- Use of Allopurinol for Prevention and Control of Hyperuricemia in Patients with Neoplastic DiseaseNew England Journal of Medicine, 1966
- Prevention of Hyperuricemia in Leukemia and LymphomaJAMA, 1965
- The Effectiveness of the Xanthine Oxidase Inhibitor Allopurinol in the Treatment of GoutAnnals of Internal Medicine, 1965
- Effect of allopurinol (4-Hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary goutThe American Journal of Medicine, 1964